OncoAlert
@OncoAlert
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨
ID:1109128247789395968
http://www.OncoAlert360.com 22-03-2019 16:22:35
90,9K Tweets
34,8K Followers
159 Following
Follow People
Spatial HLA signature may predicts response to immunotherapy in advanced renal cell carcinoma.
Nature Medicine OncoAlert #CancerResearch #oncology #kidney
nature.com/articles/s4159…
New ESMO - Eur. Oncology guidlines in advance papillary renal cancer. While there is randomised data supporting Cabo (PFS not OS) sunitinib is still weakly supported. The single arm Len/pem & Cabo/nivo data look more active and is also recommend. 2nd line data needed ow.ly/nZA050RP77l
Updated clear cell renal cancer guidlines ESMO - Eur. Oncology.Ipi/nivo now has additional weak support in IMDC good risk (I,C). Belzutifan gets strong support in 3rd line (I,B) but less strong 2nd line (VEGF TKI preferred).1st line PD1/VEGF unchanged Annals of Oncology ow.ly/nZA050RP77l
⚡️ On Nature Medicine - A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma
#KidneyCancer #Immunotherapy OncoAlert OncLive.com
nature.com/articles/s4159…
A must-read, in-depth concise review on mRNA-based cancer vaccines in oncology, including #lungcancer A rapidly evolving field, with first rand ph3 trials in the adjuvant and peri-operative setting currently enrolling patients!
#LCSM ESMO - Eur. Oncology ASCO IASLC OncoAlert
MSD Cosmos
🆕 🗞️ Annals of Oncology
The largest series to date on POL-E or POLD1 (proofreading-deficient) metastatic #ColorectalCancer and the use of #immunotherapy .
Tumors➡️MSS but have a very high TMB (ultra-hyper-mutated - TMB > 100 Mut/Mb).
ESMO - Eur. Oncology OncoAlert
sciencedirect.com/science/articl…
Publised in Journal of Clinical Oncology
👫N=44 pts with AML-FLT3m; median age 57 yrs
💊 Crenolanib + IC
🔹CRc 86% (CR 77%)
🔹FU 45 mos ➡️ median OS not reached; median EFS 44.7 mos
#leusm OncoAlert Jayastu Senapati
ascopubs.org/doi/10.1200/JC…
Pooled analysis do adaptive studies of Nivolumab followed by Ipilimumab in RCC. Lower rates of response conversion and CR. Upfront intensification preferred. Toni Choueiri, MD UC San Diego Health Moores Cancer Center UroToday.com
Today’s the deadline to submit your abstracts for #ASCOQLTY24 !
Please share your work with your colleagues to improve cancer care!
Oncology Nursing Society OncoAlert
📣 We're hosting a Meet and Greet at #ASCO24 with our #SoMe Editor Gil Morgan, MD (@OncoAlert) and Section Editors Dr. Daniel Morgensztern of Washington U. Med and Walter Stadler of UChicago Medicine! Plan a stop by the American Cancer Society booth at 4pm on Sunday right after the ASCO Plenary.